Floatz logo

hmn14

Colorectal Neoplasms

Gilead SciencesPhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
73/ 100

Competitive context

118 Active assets in the Colorectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University Cancer Hospital & Institute
Phase 4BBB
Calcium folinate pentahydrate
Janssen Research & Development, LLC
Phase 4BBB
FLUOROURACILUM
Rutgers, The State University of New Jersey
Phase 4BBB
Irinotecan
Shanghai Zhongshan Hospital
Phase 4BBB
Regorafenib
Sergey Orlov, MD
Phase 4BB

View all 50 →

Same molecule, other indications

hmn14 is also rated in:

Colorectal CarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
Rectal CancerDormant
CCC
Indicative ·
50 / 100
View asset →
Colon CancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →